GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Annji Pharmaceutical Co Ltd (ROCO:7754) » Definitions » Common Stock

Annji Pharmaceutical Co (ROCO:7754) Common Stock : NT$938.82 Mil (As of Dec. 2024)


View and export this data going back to 2024. Start your Free Trial

What is Annji Pharmaceutical Co Common Stock?

Annji Pharmaceutical Co's quarterly common stock increased from Dec. 2023 (NT$908.61 Mil) to Jun. 2024 (NT$935.75 Mil) and increased from Jun. 2024 (NT$935.75 Mil) to Dec. 2024 (NT$938.82 Mil).

Annji Pharmaceutical Co's annual common stock increased from Dec. 2022 (NT$658.76 Mil) to Dec. 2023 (NT$908.61 Mil) and increased from Dec. 2023 (NT$908.61 Mil) to Dec. 2024 (NT$938.82 Mil).


Annji Pharmaceutical Co Common Stock Historical Data

The historical data trend for Annji Pharmaceutical Co's Common Stock can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Annji Pharmaceutical Co Common Stock Chart

Annji Pharmaceutical Co Annual Data
Trend Dec21 Dec22 Dec23 Dec24
Common Stock
623.76 658.76 908.61 938.82

Annji Pharmaceutical Co Semi-Annual Data
Dec21 Dec22 Jun23 Dec23 Jun24 Dec24
Common Stock Get a 7-Day Free Trial 658.76 - 908.61 935.75 938.82

Annji Pharmaceutical Co Common Stock Calculation

Common stock is listed on the Balance Sheet at the par value of the total shares outstanding of a company.

The par value of common stocks is meaningless. It is usually set at an absurdly low number.


Annji Pharmaceutical Co Business Description

Traded in Other Exchanges
N/A
Address
Zhongxiao E. Raod, 16th Floor-6, No. 508, Sector 7, Nangang Distrist, Taipei, TWN, 115011
Annji Pharmaceutical Co Ltd is an R&D based, clinical-stage new drug company dedicated to the development of first-in-class small molecules focusing on indications with highly unmet needs in the therapeutic areas of neurology, dermatology, and inflammatory disorders, including rare diseases such as idiopathic pulmonary fibrosis and Kennedy's disease, or SBMA (Spinal and bulbar muscular atrophy). Its pipeline products include AJ201, AJ302 and AJ303.

Annji Pharmaceutical Co Headlines

No Headlines